Insight, China's Pharmaceutical Industry

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Chia Tai Tianqing Pharmaceutical Group, a wholly owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177),...

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026

Novartis AG (NYSE: NVS) announced that the Committee for Medicinal Products for Human Use (CHMP)...

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the Center for Drug Evaluation (CDE)...

Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Fineline Cube Apr 27, 2026

Brii Biosciences (HKG: 2137) unveiled a cross-study pooled analysis of hepatitis B surface antigen (HBsAg)...

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026

CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Fineline Cube Apr 27, 2026

Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) announced a landmark collaboration with Mark Cuban...

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Fineline Cube Apr 27, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced regulatory clearance from Australia’s Therapeutic Goods Administration (TGA)...

Company Drug

Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg

Fineline Cube Apr 27, 2026

Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ)...

Company Drug

AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request

Fineline Cube Apr 27, 2026

AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved...

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026

Beijing QL Biopharmaceutical Co., Ltd., a clinical-stage biotech founded in 2018, has filed a prospectus...

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Fineline Cube Apr 27, 2026

Boehringer Ingelheim, the German pharmaceutical giant, officially launched the Pulmonary Fibrosis Care Initiative late last...

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026

Sanofi (NASDAQ: SNY) announced on 24 April 2026 that the European Medicines Agency’s Committee for...

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026

Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest...

Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026

Novartis AG (NYSE: NVS) announced the voluntary withdrawal of its Type II variation application to...

Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced on 24 April 2026 a definitive agreement to...

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026

China’s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations...

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Fineline Cube Apr 27, 2026

Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) announced a definitive agreement to acquire Organon & Co....

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026

AstraZeneca plc (NYSE: AZN) announced that China’s National Medical Products Administration (NMPA) has granted approvals...

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Fineline Cube Apr 24, 2026

Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection...

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026

Star Sports Medicine Co., Ltd., a Chinese sports medical device manufacturer, successfully completed its initial...

Insight, China's Pharmaceutical Industry

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg

AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

You Missed

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma